Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lessened its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 19.8% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 435,034 shares of the company’s stock after selling 107,719 shares during the quarter. Federated Hermes Inc.’s holdings in Takeda Pharmaceutical were worth $5,760,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of TAK. Versant Capital Management Inc acquired a new stake in Takeda Pharmaceutical in the fourth quarter worth about $26,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets boosted its holdings in shares of Takeda Pharmaceutical by 416.0% in the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after acquiring an additional 2,596 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after acquiring an additional 1,976 shares during the period. Finally, Crowley Wealth Management Inc. bought a new stake in Takeda Pharmaceutical during the fourth quarter worth approximately $52,000. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK opened at $13.90 on Friday. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The company has a current ratio of 1.31, a quick ratio of 0.72 and a debt-to-equity ratio of 0.63. The firm has a 50-day moving average of $14.46 and a two-hundred day moving average of $13.90. The company has a market capitalization of $44.23 billion, a price-to-earnings ratio of 34.75, a PEG ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.